News

ProVen Growth and Income VCT's Latest Interim Management Insights

ProVen Growth and Income VCT's Latest Interim Management Insights

ProVen Growth and Income VCT plc Overview

ProVen Growth and Income VCT plc, known for its investment strategies and market presence, has released its Interim Management Statement for the recent quarter. This report highlights significant financial data and key developments that occurred from March to May 2025, offering shareholders insights into the company’s performance.

Performance at a Glance

The performance metrics of ProVen Growth and Income VCT illustrate a steady position in the market. The Net Asset Value (NAV) per share has remained consistent at 50.2 pence. This value reflects the true worth of the company, considering both its investments and the dividends paid to shareholders. Over the years, the company has successfully paid out dividends that contribute to a Total Return of 131.35 pence, combining both NAV and historical dividends since the Original 'C' Share class launch.

Key Financial Highlights

As measured at the close of May 2025, the company reported the following financial aspects:

  • Net Asset Value per Share: 50.2 pence
  • Dividends Paid: 81.15 pence since the 'C' Shares inception
  • Total Return: 131.35 pence

This performance indicates a robust position for potential investors and current shareholders alike.

Dividends and Shareholder Returns

On June 5, 2025, ProVen Growth and Income VCT announced a final dividend of 1.5 pence per share for the financial year ending February 2025. This upcoming payment, scheduled for August 15, 2025, is designed to reward shareholders, especially those on the company's register by July 18, 2025. After this dividend issuance, the NAV per share is anticipated to adjust to 48.7 pence, highlighting the corporation's commitment to delivering shareholder value.

Investment Portfolio Overview

The company has a diverse investment portfolio that continues to thrive. As of the end of May 2025, the detailed summary illustrates various investments, notably in companies like Picasso Labs, Luxury Promise, and MPB Group. Each investment plays a crucial role in bolstering ProVen's market presence.

  • Total Venture Capital Investments: £115,477,000
  • Cash at Bank: £41,759,000
  • Other Net Current Assets: £169,000

Through strategic investments, ProVen demonstrates its commitment to generating sustainable growth within its portfolio.

Recent Investment Activities

In the recent quarter, investment activities were vibrant, with several additions made to the portfolio. Noteworthy investments included:

  • Limitless Travel Ltd: £1,035,000
  • MOTH Drinks Ltd: £164,000
  • Mojo Men Ltd: £117,000

The total new investments from this quarter amounted to £1,316,000, indicating a proactive approach to expanding their investment footprint.

Changes in Share Capital

During the three-month period leading up to May 2025, the share capital experienced adjustments:

  • As at March 1, 2025: 312,422,990 shares
  • Shares Issued: 15,087,371 shares
  • Total as of May 31, 2025: 327,510,361 shares

These changes signify an active approach in managing share capital, providing liquidity and investment prospects for the shareholders.

Future Outlook and Material Events

Looking forward, ProVen Growth and Income VCT remains focused on maintaining its growth trajectory while strategically investing in high-potential ventures. There were no significant material events or adverse developments reported during the three-month period that could impact the overall strategy or outlook of the company.

Company Contact Information

For more details about the company or to inquire about investments, shareholders can reach out through the following:

Beringea LLP
Company Secretary
Telephone: 020 7845 7820

Frequently Asked Questions

What is ProVen Growth and Income VCT plc?

ProVen Growth and Income VCT plc is an investment company focused on providing returns to shareholders through various venture capital investments.

What is the latest Net Asset Value per share for ProVen?

As of May 2025, the NAV per share is reported to be 50.2 pence.

When will the next dividend be paid?

The next dividend announced is set to be paid on August 15, 2025.

What is the total return including dividends for shareholders?

The total return for shareholders, including dividends since the launch of the 'C' Shares, is 131.35 pence.

How can I contact ProVen Growth and Income VCT plc?

Contact Beringea at 020 7845 7820 for any inquiries or further information about the company.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 169

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 133

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 563

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 555

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 404

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 207

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 164

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 315

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 83

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 61

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking Interoperability: The Free Partner Edition by interop.io

Updated Category News Views 230

Unlocking New Potential in Fintech with Free Edition interop.io, known as a frontrunner in desktop interoperability, is set to revolutionize the way fintech companies operate with the introduction of a cost-free edition of their software suite, named io.Connect. This new initiative aims to provide fintechs, regardless of their size or stage, with the opportunity to adopt...

Continue Reading
Massage Envy Celebrates Scholarship Winners and Their Future

Updated Category News Views 164

Massage Envy Celebrates Scholarship Winners Eight outstanding individuals have been recognized as winners of the Massage Envy National Scholarship Sweepstakes, each receiving a $2,500 scholarship to support their journey into the massage therapy profession. This initiative demonstrates Massage Envy's commitment to fostering the next generation of talented massage...

Continue Reading
Paul Mueller Company Updates Investors on Dividend Plans

Updated Category News Views 397

Paul Mueller Company Declares Cash Dividend Paul Mueller Company (OTC: MUEL) has some exciting news for its investors. The company has recently announced that its Board of Directors has declared a cash dividend of $0.30 per share on its outstanding common stock. This dividend reflects the company’s ongoing commitment to providing value to its shareholders. Details of...

Continue Reading
Photocure Enhances Leadership with Jane Healy as GM EMEA

Updated Category News Views 360

Photocure Welcomes Jane Healy as Vice President and General Manager EMEA Photocure ASA (OSE: PHO), known as the Bladder Cancer Company, has made a significant move by appointing Jane Healy as the new Vice President and General Manager for the EMEA region. This strategic decision underscores Photocure's commitment to enhancing its leadership in the uro-oncology sector....

Continue Reading
TDS Hits Bumps but Keeps Shareholders Happy

Updated Category News Views 48

High Hopes and Hard Hits: TDS in 2026 Listen up, folks. Telephone and Data Systems, Inc. (NYSE: TDS) just popped the hood on their third quarter earnings, and it's a mixed bag with plenty to chew over. Operating revenues are slightly down from last year, but management's got some tricks up their sleeves. CEO Walter Carlson is trumpeting their expanded fiber service...

Continue Reading